Koyfin Home > Directory > Health Care > Mallinckrodt Plc

Mallinckrodt Plc Price Chart MNK

Historical daily share price chart and data for Mallinckrodt Plc since 2013 adjusted for splits and dividends. The latest closing price for Mallinckrodt Plc as of October 09, 2020 is $0.75.
  • In 2020 the stock opened at $3.58 and closed at $0.75 for a loss of -377% YTD.
  • In 2019 the stock opened at $15.61 and closed at $3.49 for a loss of -347%.
  • In 2018 the stock opened at $22.82 and closed at $15.80 for a loss of -44%.
  • In 2017 the stock opened at $50.50 and closed at $22.56 for a loss of -124%.
View Chart On Koyfin

Mallinckrodt Plc Summary

Stock Symbol: MNK

Mallinckrodt Plc Company Info

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Dublin, Ireland.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
4172.45 %
30D Volatility
Hedge Fund Held
14.25 %

Last 10 Days of MNK Prices